As­traZeneca says its block­buster Farx­i­ga proved to be a game-chang­er in CKD — wrap­ping PhI­II ear­ly

If the FDA can still hold up its end of the bar­gain, As­traZeneca is al­ready on a short path to scoop­ing up a cut­ting-edge win with a like­ly ap­proval for their SGLT2 drug Farx­i­ga in cut­ting the risk of heart fail­ure. Now the phar­ma gi­ant says it can point to sol­id ev­i­dence that the drug — ini­tial­ly re­strict­ed to di­a­betes — al­so works for chron­ic kid­ney dis­ease, po­ten­tial­ly adding a block­buster in­di­ca­tion for the fran­chise.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER